Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
  • Facebook
  • Twitter / X
  • Instagram
  • Youtube
BhaskarLive.in Bhaskar Live

Bhaskar English News

BhaskarLive.in Bhaskar Live

Bhaskar English News

  • TOP NEWS
  • NATIONAL
  • WORLD
  • ENTERTAINMENT
  • BUSINESS
  • SCIENCE
  • HEALTH
  • SPORTS
  • TOP NEWS
  • NATIONAL
  • WORLD
  • ENTERTAINMENT
  • BUSINESS
  • SCIENCE
  • HEALTH
  • SPORTS
Subscribe
Close

Search

TOP NEWS

Alkem Laboratories’ Q1 net profit falls 22 pc to Rs 520 crore

By IANS
August 14, 2026 2 Min Read

Mumbai, Aug 14 (IANS) Alkem Laboratories on Friday reported a 21.7 per cent year-on-year (YoY) decline in consolidated net profit for the first quarter of current financial year (Q1 FY27).

The drugmaker posted a net profit of Rs 520 crore in Q1 FY27, compared with Rs 664 crore in the corresponding quarter of the previous financial year (Q1 FY26), according to its stock exchange filing.

Revenue from operations rose 10.9 per cent year-on-year to Rs 3,740 crore from Rs 3,371 crore a year earlier.

Growth was driven by both domestic and international businesses. India sales increased 10.3 per cent to Rs 2,497.8 crore, while international sales climbed 16 per cent to Rs 1,222.3 crore.

At the operating level, Alkem reported healthy performance during the quarter. EBITDA rose 16.2 per cent year-on-year to Rs 766.6 crore from Rs 660 crore in the year-ago period.

EBITDA margin improved to 20.5 per cent from 19.6 per cent, as per its regulatory filing.

However, the company’s tax expense surged to Rs 251 crore during the quarter, compared with Rs 103 crore in the corresponding period last financial year, weighing on bottom-line growth.

Commenting on the results, Managing Director Sandeep Singh said Alkem had begun FY27 on a steady note, supported by healthy growth in both its India and international businesses.

“We have started FY27 on a steady note, with healthy growth across our India and international businesses. Our India business continued to outperform the market, while the strong growth in our non-US international markets was encouraging,” he said.

“At the same time, there are areas where we need to improve, particularly in strengthening execution, addressing operational and regulatory priorities, and improving the consistency of performance across our businesses,” Singh added.

We are also investing in R&D, MedTech and Biotech as we build our next phase of growth. Our focus will be to strengthen the core, address the areas that need improvement and build these newer opportunities in a disciplined manner, he mentioned further.

–IANS

pk

Tags:

Health News
Author

IANS

Follow Me
Other Articles
Previous

Juniper Hotels to Invest Rs 850 Crore to Develop Landmark Luxury Hotel in New Delhi

Next

Natco Pharma Q1 net profit slumps 57 pc on weak Lenalidomide sales

No Comment! Be the first one.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

News Categories

  • 1
  • BUSINESS
  • EDUCATION
  • ENTERTAINMENT
  • FINANCE
  • HEALTH AND MEDICINE
  • INTERNATIONAL
  • NATIONAL
  • public
  • SCIENCE AND TECHNOLOGY
  • SPORTS
  • TOP NEWS

About us

Bhaskar Live (bhaskarlive.in) is an English-language digital news portal that provides real-time coverage of national and international news, focusing on India-centric stories with a mix of original reporting and syndicated content. Launched in 2016, it serves as the English arm of the Dainik Bhaskar Group, one of India's largest media conglomerates known primarily for its Hindi-language newspaper, Dainik Bhaskar. The site is owned by Bhaskar Prakashan Pvt. Ltd.,

Terms of use

By accessing BhaskarLive.in, you agree to these Terms. This site provides news and information for personal, non-commercial use only. All content is copyrighted; reproduction requires written permission. You must not post unlawful, defamatory, or infringing material. We disclaim all warranties; content is provided "as is" without guarantees of accuracy. BhaskarLive.in is not liable for any damages from use. These Terms are governed by Madhya Pradesh law. We may update them anytime—continued use implies acceptance. Contact: bhaskarlive2019@gmail.com.

Disclaimer

This news is automatically published via auto feeds. No changes or modifications (editing) of any kind have been made to this news by the bhaskarlive.in team. The entire responsibility for this news and the materials used in it lies solely with the news agency. Before using the information provided in this news, please consult experts in the relevant field (lawyer / engineer / astrologer / vastu expert / doctor / news agency / other subject experts). Therefore, bhaskarlive.in news portal bears no responsibility for the related news and the text matter, photos, videos, and audio used.

Advertise with us

Email: bhaskarlive2019@gmail.com
Mobile: +91 - 9770324452
WhatsApp: +91 - 9424358037

Contact us

Bhaskar Prakashan Pvt. Ltd.
Email: bhaskarlive2019@gmail.com
Mobile: +91 - 9770324452
WhatsApp: +91 - 9424358037
Address: Bishambhar Bhavan, 18, Civic Centre, Jabalpur- 482002, Madhya Pradesh, India - 482004
Copyright 2026 — Bhaskar Live. All rights reserved.